Drug Free Solution, Inc.
DSOL · OTC
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Income | -$0 | -$0 | -$0 | -$1 |
| % Margin | – | – | – | -174,817.4% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$1 |
| % Margin | – | – | – | -174,816.8% |
| EPS | 0 | 0 | -0 | -0.003 |
| % Growth | – | 100% | 97% | – |
| EPS Diluted | 0 | 0 | -0 | -0.003 |
| Weighted Avg Shares Out | 283 | 444 | 444 | 428 |
| Weighted Avg Shares Out Dil | 283 | 444 | 444 | 428 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$1 |
| % Margin | – | – | – | -173,282.9% |